Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 3:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 169 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Human Development Clear all
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte Maturation

NCT01606709
View directory record Official record
Conditions
Endometrial Receptivity, Ovarian Hyperstimulation Syndrome
Interventions
GnRH agonist, hCG
Drug
Lead sponsor
UConn Health
Other
Eligibility
21 Years to 33 Years · Female only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 21, 2018 · Synced Oct 22, 2026, 3:21 AM EDT
Terminated Phase 4 Interventional Results available

Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])

NCT00328926
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism
Interventions
Luveris® 75 IU, Luveris® 25 IU, Placebo, Recombinant human follicle stimulating hormone (r-hFSH), Recombinant human chorionic gonadotropin (r-hCG)
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2013 · Synced Oct 22, 2026, 3:21 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain Health Together: Development and Pilot Test

NCT06914947
View directory record Official record
Conditions
Cognitive Impairment, Subjective Cognitive Decline, Mild Cognitive Impairment (MCI)
Interventions
Brain Health Together
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
65 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Oct 22, 2026, 3:21 AM EDT
Completed No phase listed Observational

Impact of Drug Therapy and Co-Morbidities on the Development of Renal Impairment in HIV-Infected Patients

NCT00551655
View directory record Official record
Conditions
Human Immunodeficiency Viruses, Kidney Failure, HIV Infections
Interventions
Not listed
Lead sponsor
AIDS Arms Inc.
Other
Eligibility
18 Years and older
Enrollment
684 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2007 · Synced Oct 22, 2026, 3:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Pharmacodynamics of Long Acting Human Growth Hormone (hGH) Product (MOD-4023) in Healthy Caucasian and Japanese Volunteers

NCT02418767
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
MOD-4023, Placebo
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Oct 22, 2026, 3:21 AM EDT
Completed Phase 3 Interventional Results available

A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency

NCT03305016
View directory record Official record
Conditions
Growth Hormone Deficiency, Pediatric, Endocrine System Diseases, Hormone Deficiency, Pituitary Diseases
Interventions
TransCon hGH
Drug
Lead sponsor
Ascendis Pharma Endocrinology Division A/S
Industry
Eligibility
6 Months to 17 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 22, 2026, 3:21 AM EDT
Recruiting Phase 2 Interventional

Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT)

NCT05355272
View directory record Official record
Conditions
Gulf War Syndrome, Adult Growth Hormone Deficiency
Interventions
Recombinant human growth hormone
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 22, 2026, 3:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Metabolism and Pharmacokinetics of Primaquine Enantiomers in Human Volunteers, Study 1

NCT02898779
View directory record Official record
Conditions
Malaria
Interventions
Primaquine, R-Primaquine, S-Primaquine, SR Primaquine
Drug
Lead sponsor
University of Mississippi, Oxford
Other
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Oxford, Mississippi
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Oct 22, 2026, 3:21 AM EDT
Terminated Phase 2 Interventional Results available

A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults

NCT04493216
View directory record Official record
Conditions
HIV Infections
Interventions
GSK3640254, ABC/3TC, FTC/TAF, Dolutegravir, Placebo
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
9
States / cities
Los Angeles, California • Ft. Pierce, Florida • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 22, 2026, 3:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Challenge Model for Assessment of Human TB Immunity

NCT01868464
View directory record Official record
Conditions
Tuberculosis
Interventions
BCG TICE strain
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Decatur, Georgia • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 22, 2026, 3:21 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

In Vitro Maturation (IVM) of Human Oocytes

NCT01550861
View directory record Official record
Conditions
Infertility
Interventions
in vitro maturation, Polar Body Biopsy with preimplantation genetic screening
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
25 Years to 42 Years · Female only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 22, 2026, 3:21 AM EDT
Recruiting No phase listed Observational

Human Epilepsy Genetics--Neuronal Migration Disorders Study

NCT00041600
View directory record Official record
Conditions
Brain Malformation, Neuronal Migration Disorder, Cognition Disorder, Epilepsy
Interventions
Not listed
Lead sponsor
Harvard University Faculty of Medicine
Other
Eligibility
Not listed
Enrollment
3,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 22, 2026, 3:21 AM EDT
Suspended No phase listed Observational Accepts healthy volunteers

Post-Discharge Growth and Development of Infants Who Received Targeted Fortification in the NICU

NCT04190875
View directory record Official record
Conditions
Premature Infants
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Months to 24 Months
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 22, 2026, 3:21 AM EDT
Completed No phase listed Observational

Evaluating Human-Machine Interfaces in a Robotic Thumb Orthosis

NCT01973426
View directory record Official record
Conditions
Hemiplegic Stroke, Hemiplegic Cerebral Palsy
Interventions
Isolated Orthosis for Thumb Actuation (IOTA)
Device
Lead sponsor
Wyss Institute at Harvard University
Other
Eligibility
7 Years to 16 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Oct 22, 2026, 3:21 AM EDT
Completed Phase 2 Interventional

Study of an Extended-Release, Crystalline Formulation of Recombinant Human Growth Hormone (ALTU-238) in Growth Hormone Deficient Adults to Determine Pharmacokinetics, Pharmacodynamics, and Drug Safety

NCT00297713
View directory record Official record
Conditions
Adult Growth Hormone Deficiency
Interventions
ALTU-238
Drug
Lead sponsor
Altus Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
3
States / cities
Louisville, Kentucky • Galveston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2006 · Synced Oct 22, 2026, 3:21 AM EDT
Recruiting Phase 1Phase 2 Interventional

Melpida: Recombinant Adeno-associated Virus (Serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt)

NCT05518188
View directory record Official record
Conditions
Spasticity, Muscle, Microcephaly, Intellectual Deficiency, Growth Retardation, SPG50, Spastic Paraplegia
Interventions
MELPIDA
Biological
Lead sponsor
Elpida Therapeutics SPC
Industry
Eligibility
4 Months to 10 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 22, 2026, 3:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults

NCT04723602
View directory record Official record
Conditions
Ebola Virus Disease, Marburg Virus Disease
Interventions
cAd3-Marburg, cAd3-EBO-S
Biological
Lead sponsor
Albert B. Sabin Vaccine Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Oct 22, 2026, 3:21 AM EDT
Active, not recruiting Not applicable Interventional

HELIOS: Human Embryo Illumination to Enhance Development

NCT07311928
View directory record Official record
Conditions
IVF Outcomes
Interventions
Photobiomodulation
Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 48 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 22, 2026, 3:21 AM EDT
Recruiting Phase 1Phase 2 Interventional

A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy

NCT07227857
View directory record Official record
Conditions
Epileptic Encephalopathy
Interventions
S230815- Starting dose A, S230815- Dose B, S230815- Dose C, S230815- Dose D
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
2 Years to 12 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Orange, California • Boston, Massachusetts • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 22, 2026, 3:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Escalation Study of GSK2838232 in Healthy Subjects

NCT01802918
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK2838232, Placebo, Ritonavir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 22, 2026, 3:21 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Outcomes Mandate National Integration With Cannabis as Medicine

NCT03944447
View directory record Official record
Conditions
Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma, Fibromyalgia, Seizures, Hepatitis C, Cancer, Crohn Disease, HIV/AIDS, Multiple Sclerosis, Traumatic Brain Injury, Sickle Cell Disease, Post Traumatic Stress Disorder, Tourette Syndrome, Ulcerative Colitis, Glaucoma, Epilepsy, Inflammatory Bowel Diseases, Parkinson Disease, Amyotrophic Lateral Sclerosis, Chronic Traumatic Encephalopathy, Anxiety, Depression, Insomnia, Autism, Opioid-use Disorder, Bipolar Disorder, Covid19, SARS-CoV Infection, COVID-19, Corona Virus Infection, Coronavirus
Interventions
Cannabis, Medical, RYAH-Medtech Inhaler
Drug · Device
Lead sponsor
OMNI Medical Services, LLC
Network
Eligibility
7 Years and older
Enrollment
200,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
17
States / cities
Boca Raton, Florida • Bradenton, Florida • Fort Lauderdale, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Oct 22, 2026, 3:21 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of a Vaccine Against Enterotoxigenic Escherichia Coli (ETEC) to Prevent Moderate to Severe Diarrhea

NCT01060748
View directory record Official record
Conditions
Diarrhea
Interventions
ACE527, Placebo
Biological
Lead sponsor
TD Vaccines A/S
Industry
Eligibility
18 Years to 50 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 7, 2011 · Synced Oct 22, 2026, 3:21 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Synergistic Activity of Human Milk Nutrients and Infant Cognition

NCT03838536
View directory record Official record
Conditions
Breastfeeding, Exclusive
Interventions
Whole Egg Powder, Egg White Powder
Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
3 Months to 35 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 22, 2026, 3:21 AM EDT
Completed No phase listed Observational

rhGH Therapy on Hepatic Drug Metabolism

NCT00458991
View directory record Official record
Conditions
Growth Hormone Deficiency, Dwarfism
Interventions
Dextromethorphan and Caffeine
Drug
Lead sponsor
University of Louisville
Other
Eligibility
4 Years to 14 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
4
States / cities
San Diego, California • Louisville, Kentucky • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Oct 22, 2026, 3:21 AM EDT